New Intraocular Lens: ZEI is now offering cataract surgeons more poibilities rough the introduction of the CT LUCIA hydrophobic monofocal intraocular lens

JENA/Germany, LONDON/UK, 13.09.2014.

At this years summer meeting of the European Society of Cataract and Refractive Surgery (ESCRS) in London medical technology provider ZEISS is presenting a new aspheric monofocal IOL. The C-loop design of the CT LUCIA has been implemented using glistening-free hydrophobic material. An innovative preloaded injector enables outstanding ease of use. With the introduction of this new product, ZEISS now offers the most comprehensive IOL portfolio in the market for all applications and requirements.

ZEISS is strengthening its offering of monofocal IOLs for cataract surgeons with the addition of the new CT LUCIA IOL featuring a C-loop design. It is made of glistening-free material and incorporates ZEISS aspheric aberration correcting optics. It is available with a fully preloaded injector system that guarantees excellent ease of use and smooth unfolding of the IOL. Due to the optical design of the lens, patients benefit from enhanced visual outcomes . The lens offers cataract surgeons streamlined workflows before and during the surgery.

"With the most comprehensive IOL portfolio on the market, we can now address the needs of all customer segments,", says Dr. Ludwin Monz, CEO of Carl Zeiss Meditec AG. "The new lens stands for ZEISS standards in optics and quality."

ZEISS already offers a wide variety of hydrophilic IOLs with an extensive diopter range which are suitable for Micro Incision Cataract Surgery (MICS). As a solutions provider, ZEISS is additionally presenting a complete workflow for cataract surgery to its customers. Each individual component meets the highest requirements. In combination, they optimize the workflow starting from gold standard biometry to visualization solutions for IOL implantation.

The new CT LUCIA is going to be on display at the ZEISS booth during the ESCRS.

The C-loop design of the new IOL CT LUCIA has been implemented using glisteing-free hydrophobic biomaterial.

With ints innovative preloaded injector the CT LUCIA form ZEISS enables outstanding ease of use.

Maedel S et al. Effect of heparin coating of a foldable intraocular lens on inflammation and capsular bag performance

after cataract surgery. JCRS 2013

Rosca, G. High Precision Injection with a New Heparin Coated Hydrophobic One Piece IOL , presented at ASCRS,

Chicago, 2012.

Jann Gerrit Ohlendorf

Director Corporate Communications

Carl Zeiss Meditec AG

Phone: +49 3641 220-331

Fax: +49 3641 220-332

press.meditec@zeiss.com

Sebastian Frericks

Investor Relations

Carl Zeiss Meditec AG

Phone: +49 3641 220-116

investors.meditec@zeiss.com

Carl Zeiss Meditec AG

Carl Zeiss Meditec AG (ISIN: DE0005313704) is one of the world's leading medical technology companies. The company supplies innovative technologies and application-oriented solutions designed to help doctors improve the quality of life of their patients. It provides complete packages of solutions for the diagnosis and treatment of eye diseases, including implants and consumables. The company creates innovative visualization solutions in the field of microsurgery. The medical technology portfolio of Carl Zeiss Meditec is rounded off by promising, future-oriented technologies such as intraoperative radiotherapy. In fiscal year 2012/2013 (ended 30 September) the Groups more than 2,500 employees generated revenue of 906 million. Carl Zeiss Meditec headquarters are located in Jena, Germany.

The company has subsidiaries in Germany and abroad; more than 50 percent of its employees are based in the USA, Japan, Spain and France. The Center for Application and Research in India (CARIn) in Bangalore, India, and the Carl Zeiss Innovation Center for Research and Development in Shanghai, China, strengthen the companys presence in these fast-growing countries. Around 35 percent of Carl Zeiss Meditec shares are in free float. The remaining approx. 65 percent are held by Carl Zeiss AG, one of the world's leading groups in the optical and optoelectronic industries.

ZEISS has offered innovative solutions and improved peoples quality of life in the future-oriented markets for Industrial Solutions, Research Solutions, Medical Technology and Consumer Optics for more than 160 years. Carl Zeiss AG, Oberkochen, is fully owned by the Carl Zeiss Foundation.

Number: 0114-2014-ENG OP

Number of Words: 462

Number of Characters: 3632

LINK:	http://applications.zeiss.com/C1256A770030BCE0/WebViewTopNewsAllE/DD9E...
	See more stories from zeiss

Most recent headlines